Testosterone treatment; Doctors have long mulled over using low doses of the hormone testosterone as a way to improve sexual function in some women, but evidence on its safety and efficacy has been somewhat lacking until now. A paper published in the journal The Lancet on Thursday found testosterone to be effective for postmenopausal women with low sexual desire; also the treatment was safer when administer as a skin patch or cream, rather than orally.
Researchers review 46 previously publish reports of 36 randomize control trials involving testosterone treatment; so that were completed between 1990 and 2018. The researchers took a close look at how testosterone affect sexual function, cognitive measures, cholesterol and other health outcomes in the trials; which include 8,480 women ages 18 to 75.
The researchers wrote in the new paper that their review provides “robust support” for a clinical trial of testosterone; so treatment to be conduct in postmenopausal women. “Further research is need to clarify the effects of testosterone treatment in premenopausal women; also the effects on musculoskeletal and cognitive health and long-term safety,” they wrote.
The researchers found that, compare with a placebo or another hormone treatment such as estrogen; hence by taking testosterone for at least 12 weeks significantly increase sexual desire, pleasure, arousal, orgasm, responsiveness, self-image and the frequency of satisfactory sexual events in postmenopausal women. The data from those previous reports also show that testosterone significantly reduce report sexual concerns and distress among the women when compare with a placebo or another form of hormone treatment.
As for premenopausal women, the only observe benefit in the data was a reduction; hence in sexually associate personal distress see in one small study. When examining the various ways testosterone be administer; so the researchers found that a significant rise in “bad” LDL cholesterol and reductions in total cholesterol, HDL cholesterol and triglycerides was see when testosterone was administer orally but not as a skin patch or cream.
Treatment of choice
“The message is that oestrogen-containing HRT should still be the treatment; which of choice for almost all menopausal women,” Jayasena said. “However, testosterone could be add to HRT when menopausal women; have sexual symptoms which are persistent. More research is need when it comes to testosterone for women, Dr. Rossella Nappi; hence of the IRCCS San Matteo Foundation and the University of Pavia in Italy, wrote in an editorial that accompany the new paper.
“Many testosterone formulations are available to improve measures of sexual well being including low sex drive and poor sexual function. However, currently, these compounds are available only as male formulations and their safety or adverse events; which as well as their effect on general aspects of women’s health; so remain controversial because of scant publish data,” Nappi wrote.
Notwithstanding the new paper, additional research should look into the therapeutic role of testosterone; hence for women through studies on the benefits and risks, she wrote: “In particular, there is an urgent need in the area of sexual medicine; hence to ensure gender equality in treating effectively those women with female sexual dysfunction.”